News archive
Showing 745 results
November 2016
-
Media Release
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
Entresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril (1)These… -
Media Release
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
-
Media Release
Alcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting
This is the latest addition to the Alcon AIR OPTIX® portfolio of monthly replacement contact lenses which merges two unique technologiesSmartShield® Technology provides excellent deposit resistance… -
Media Release
Alcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting
-
Media Release
Novartis partners with prominent US health advocacy organizations to launch first social networking platform for heart failure patients and their loved ones
Together in HF social network is an innovative resource for information and support and a place to meet others with similar health experiencesNearly 6 million Americans have heart failure (HF), a… -
Media Release
Novartis partners with prominent US health advocacy organizations to launch first social networking platform for heart failure patients and their loved ones
October 2016
-
Media Release
Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years
-- New data at EADV show Cosentyx delivers almost clear or completely clear skin in majority of patients (PASI 90 - 66%, PASI 100 - 44%) after four years of treatment1-- Data show that with Cosentyx… -
Media Release
Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years
September 2016
-
Media Release
Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
- Ilaris® (canakinumab) is the first and only FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF(1)- These three simultaneous approvals conducted under FDA Priority Review… -
Media Release
Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
-
Media Release
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
New analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores…